Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Nov 30;15(11):e0242785.
doi: 10.1371/journal.pone.0242785. eCollection 2020.

Impact of progressive resistance training on CT quantified muscle and adipose tissue compartments in pancreatic cancer patients

Affiliations
Randomized Controlled Trial

Impact of progressive resistance training on CT quantified muscle and adipose tissue compartments in pancreatic cancer patients

Raoul Wochner et al. PLoS One. .

Abstract

Objectives: Loss of body weight is often seen in pancreatic cancer and also predicts poor prognosis. Thus, maintaining muscle mass is an essential treatment goal. The primary aim was to investigate whether progressive resistance training impacts muscle and adipose tissue compartments. Furthermore, the effect of body composition on overall survival (OS) was investigated.

Methods: In the randomized SUPPORT-study, 65 patients were assigned to 6-month resistance training (2x/week) or a usual care control group. As secondary endpoint, muscle strength of the upper and lower extremities was assessed before and after the intervention period. Routine CT scans were assessed on lumbar L3/4 level for quantification of total-fat-area, visceral-fat-area, subcutaneous-fat-area, intramuscular-fat-area, visceral-to-subcutaneous fat ratio (VFR), muscle-area (MA), muscle-density and skeletal-muscle-index (SMI). OS data were retrieved.

Results: Of 65 patients, 53 had suitable CT scans at baseline and 28 completed the intervention period with suitable CT scans. There were no significant effects observed of resistance training on body composition (p>0.05; effect sizes ω2p <0.02). Significant moderate to high correlations were found between MA and muscle strength parameters (r = 0.57-0.85; p<0.001). High VFR at baseline was a predictor of poor OS (VFR≥1.3 vs. <1.3; median OS 14.6 vs. 45.3 months; p = 0.012). Loss of muscle mass was also a predictor of poor OS (loss vs. gain of SMI; median OS 24.6 vs. 50.8 months; p = 0.049).

Conclusion: There is anabolic potential in patients with resectable pancreatic cancer. A progressive resistance training may help patients to maintain their muscle mass and avoid muscle depletion. CT-quantified muscle mass at the level of L3/4 showed a good correlation to muscle strength. Therefore, maintaining muscle mass and muscle strength through structured resistance training could help patients to maintain their physical functioning. A high VFR at baseline and a high loss of muscle mass are predictors of poor OS. Registered on ClinicalTrials.gov (NCT01977066).

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient flow chart.
T0 = baseline; T2 = after 6-month resistance training; * Combining RT1 and RT2.
Fig 2
Fig 2. Kaplan-Meier-curve for VFR at T0.
Log-rank-test, n = 53. Patients with high VFR (≥1.3; n = 8; continuous line) show a lower median overall survival of 14.6 months than patients with low VFR (<1.3; n = 45; dotted line) with a median overall survival of 45.3 months (p = 0.012).
Fig 3
Fig 3. Kaplan-Meier-curve for difference in SMI150 from T0 to T2.
Log-rank-test, n = 28. Patients with loss of muscle mass (SMI150-difference < 0 cm2/m2; n = 12, continuous line) show a median overall survival of 24.6 months vs. patients with gain of muscle mass (SMI150-difference ≥ 0 cm2/m2, n = 16; dotted line) and a median survival of 50.8 months (p = 0.049).

Similar articles

Cited by

References

    1. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980;69(4):491–7. 10.1016/s0149-2918(05)80001-3 - DOI - PubMed
    1. Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, et al. Pancreas Cancer-Associated Weight Loss. Oncologist. 2018. Epub 2018/12/29. 10.1634/theoncologist.2018-0266 - DOI - PMC - PubMed
    1. Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol. 2016;4(3):315–25. Epub 2016/03/22. 10.3892/mco.2015.716 - DOI - PMC - PubMed
    1. Idachaba S, Dada O, Abimbola O, Olayinka O, Uma A, Olunu E, et al. A Review of Pancreatic Cancer: Epidemiology, Genetics, Screening, and Management. Open Access Maced J Med Sci. 2019;7(4):663–71. Epub 2019/03/22. 10.3889/oamjms.2019.104 - DOI - PMC - PubMed
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. 10.1016/S1470-2045(10)70218-7 - DOI - PubMed

Publication types

Associated data